Browse > Article
http://dx.doi.org/10.4046/trd.2012.72.2.149

Systemic Corticosteroid Treatment in Severe Community-Acquired Pneumonia Requiring Mechanical Ventilation: Impact on Outcomes and Complications  

Lee, Seung-Jun (Department of Internal Medicine, Gyeongsang National University College of Medicine)
Lee, Seung-Hun (Department of Internal Medicine, Gyeongsang National University College of Medicine)
Kim, You-Eun (Department of Internal Medicine, Gyeongsang National University College of Medicine)
Cho, Yu-Ji (Department of Internal Medicine, Gyeongsang National University College of Medicine)
Jeong, Yi-Yeong (Department of Internal Medicine, Gyeongsang National University College of Medicine)
Kim, Ho-Cheol (Department of Internal Medicine, Gyeongsang National University College of Medicine)
Lee, Jong-Deog (Department of Internal Medicine, Gyeongsang National University College of Medicine)
Kim, Jang-Rak (Gyeongsang Institute of Health Sciences, Gyeongsang National University College of Medicine)
Hwang, Young-Sil (Department of Internal Medicine, Gyeongsang National University College of Medicine)
Publication Information
Tuberculosis and Respiratory Diseases / v.72, no.2, 2012 , pp. 149-155 More about this Journal
Abstract
Background: This study is to evaluate the effect of systemic corticosteroid on the clinical outcomes and the occurrence of complications in mechanical ventilated patients with severe community-acquired pneumonia (CAP). Methods: We retrospectively assessed the clinical outcomes and complications in patients with severe CAP admitted to ICU between March 1, 2003 and July 28, 2009. Outcomes were measured by hospital mortality after ICU admission, duration of mechanical ventilation (MV), ICU, and hospital stay. Complications such as ventilator associated pneumonia (VAP), catheter related-blood stream infection (CR-BSI), and upper gastrointestinal (UGI) bleeding during ICU stay were assessed. Results: Of the 93 patients, 36 patients received corticosteroids over 7 days while 57 patients did not receive corticosteroids. Age, underlying disease, APACHE II, PSI score, and use of vasopressor were not different between two groups. In-hospital mortality was 30.5% in the steroid group and 36.8% in the non-steroid group (p>0.05). The major complications such as VAP, CR-BSI and UGI bleeding was significantly higher in the steroid group than in the non-steroid group (19.4% vs. 7%, p<0.05). The use of steroids and the duration of ICU stay were significantly associated with the development of major complications during ones ICU stay (p<0.05). Conclusion: Systemic corticosteroid in patients with severe CAP requiring mechanical ventilation may have no beneficial effect on clinical outcomes like duration of ICU stay and in-hospital mortality but may contribute to the development of ICU acquired complications.
Keywords
Pneumonia, Community-Acquired; Adrenal Cortex Hormones; Respiration, Artificial; Mortality; complications;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Walters JA, Gibson PG, Wood-Baker R, Hannay M, Walters EH. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2009;(1):CD001288.
2 Snijders D, Daniels JM, de Graaff CS, van der Werf TS, Boersma WG. Efficacy of corticosteroids in community- acquired pneumonia: a randomized double-blinded clinical trial. Am J Respir Crit Care Med 2010;181:975-82.   DOI
3 Meduri GU, Golden E, Freire AX, Taylor E, Zaman M, Carson SJ, et al. Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial. Chest 2007;131:954-63.   DOI
4 Fardet L, Kassar A, Cabane J, Flahault A. Corticosteroidinduced adverse events in adults: frequency, screening and prevention. Drug Saf 2007;30:861-81.   DOI
5 Annane D, Sébille V, Charpentier C, Bollaert PE, François B, Korach JM, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002; 288:862-71.   DOI
6 Salluh JI, Soares M, Coelho LM, Bozza FA, Verdeal JC, Castro-Faria-Neto HC, et al. Impact of systemic corticosteroids on the clinical course and outcomes of patients with severe community-acquired pneumonia: a cohort study. J Crit Care 2011;26:193-200.   DOI
7 Chon GR, Lim CM, Koh Y, Hong SB. Analysis of systemic corticosteroid usage and survival in patients requiring mechanical ventilation for severe community- acquired pneumonia. J Infect Chemother 2011;17: 449-55.   DOI
8 Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997;336:243-50.   DOI
9 Koenig SM, Truwit JD. Ventilator-associated pneumonia: diagnosis, treatment, and prevention. Clin Microbiol Rev 2006;19:637-57.   DOI
10 Calandra T, Cohen J; International Sepsis Forum Definition of Infection in the ICU Consensus Conference. The international sepsis forum consensus conference on definitions of infection in the intensive care unit. Crit Care Med 2005;33:1538-48.   DOI
11 Cook D, Heyland D, Griffith L, Cook R, Marshall J, Pagliarello J. Risk factors for clinically important upper gastrointestinal bleeding in patients requiring mechanical ventilation. Canadian Critical Care Trials Group. Crit Care Med 1999;27:2812-7.   DOI
12 Marik P, Kraus P, Sribante J, Havlik I, Lipman J, Johnson DW. Hydrocortisone and tumor necrosis factor in severe community-acquired pneumonia. A randomized controlled study. Chest 1993;104:389-92.   DOI
13 Mikami K, Suzuki M, Kitagawa H, Kawakami M, Hirota N, Yamaguchi H, et al. Efficacy of corticosteroids in the treatment of community-acquired pneumonia requiring hospitalization. Lung 2007;185:249-55.   DOI
14 Gogos CA, Drosou E, Bassaris HP, Skoutelis A. Proversus anti-inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options. J Infect Dis 2000;181:176-80.   DOI
15 Bauer TT, Montón C, Torres A, Cabello H, Fillela X, Maldonado A, et al. Comparison of systemic cytokine levels in patients with acute respiratory distress syndrome, severe pneumonia, and controls. Thorax 2000; 55:46-52.   DOI
16 Salluh JI, Póvoa P, Soares M, Castro-Faria-Neto HC, Bozza FA, Bozza PT. The role of corticosteroids in severe community-acquired pneumonia: a systematic review. Crit Care 2008;12:R76.   DOI
17 Annane D, Meduri GU. Corticosteroids for community- acquired pneumonia: time to act! Crit Care 2008;12:166.   DOI
18 Sibila O, Agustí C, Torres A. Corticosteroids in severe pneumonia. Eur Respir J 2008;32:259-64.   DOI
19 Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001;163:1730-54.   DOI
20 Confalonieri M, Urbino R, Potena A, Piattella M, Parigi P, Puccio G, et al. Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med 2005;171: 242-8.   DOI
21 Woodhead M, Welch CA, Harrison DA, Bellingan G, Ayres JG. Community-acquired pneumonia on the intensive care unit: secondary analysis of 17,869 cases in the ICNARC Case Mix Programme Database. Crit Care 2006;10 Suppl 2:S1.
22 Garcia-Vidal C, Calbo E, Pascual V, Ferrer C, Quintana S, Garau J. Effects of systemic steroids in patients with severe community-acquired pneumonia. Eur Respir J 2007;30:951-6.   DOI
23 Siempos II, Vardakas KZ, Kopterides P, Falagas ME. Adjunctive therapies for community-acquired pneumonia: a systematic review. J Antimicrob Chemother 2008; 62:661-8.   DOI